The present study indicates the mutual role of HPSE and HPSE2 regulatory elements in the manifestation of multiple myeloma and proposes the use of heparanase 2-mimicking drugs for a most pronounced suppression of heparanase activity in multiple myeloma accompanied by EMD and osteolytic bone disease. The gene discussed is HPSE; the disease is plasma cell myeloma.